West Virginia Reaches Settlement with Juul Labs Inc.

Apr.11.2023
West Virginia Reaches Settlement with Juul Labs Inc.
West Virginia settles lawsuit with Juul for $7.9 million over allegations of unfair or fraudulent practices targeting minors.

The state of West Virginia has reached a settlement with e-cigarette manufacturer Juul Labs Inc. (hereafter referred to as Juul) over allegations that the company violated the state's consumer credit and protection laws.


Electronic cigarette manufacturer Juul has agreed to pay a $7.9 million settlement to the state. The company has been accused of engaging in unfair or deceptive practices, particularly targeted towards minors, in the manufacturing, design, sales, marketing, promotion, and distribution of e-cigarettes within the state. According to State Attorney General Patrick Morrisey, the settlement will prevent companies like Juul from adopting marketing strategies that target minors. Morrisey stated that the company was accused of deceiving consumers about the nicotine content, misrepresenting the nicotine equivalency between their products and traditional cigarettes, and underestimating the addictive risks associated with their high nicotine levels.


According to a statement from Austin Finan, Vice President of Corporate Communications for Juul Labs, this settlement represents "another step in Juul Labs' ongoing commitment to address the company's past issues.


According to Finan, the terms of the settlement agreement are similar to previous settlements and provide financial resources for further efforts to combat underage smoking and develop smoking cessation programs. This reflects the current business practices that have been implemented since the company's comprehensive relaunch in the fall of 2019. Given that West Virginia has the highest smoking rate in the United States, the company hopes that some of the funds will be directly used to reduce smoking and improve public health within the state.


According to Finan, Juul has reached a settlement with "40 states and regions, providing billions of dollars for participating states." As reported by 2FIRSTS before, Juul has already paid over $2.6 billion in settlements to different states. Finan stated, "This settlement is based on us resolving private lawsuits across the country and covers over 5,000 cases brought by approximately 10,000 plaintiffs.


According to data from the US Centers for Disease Control and Prevention (CDC), Juul e-cigarettes contain high levels of nicotine - the amount of nicotine in one Juulpod is equivalent to 20 regular cigarettes. However, the defense disagrees with this data, arguing that the total amount of nicotine in Juulpods is "equivalent to 1.72 packs (34 cigarettes).


The amount of nicotine contained in one Juulpod is equivalent to at least 20 regular cigarettes, according to a photo source provided by the Associated Press.


In 2017, 14.3% of high school students in West Virginia reported using e-cigarettes for at least one day in the past 30 days. This figure was slightly higher than the national average of 13.2%.


According to data from the 2019 National Youth Tobacco Survey, over 5 million American middle and high school students are currently using e-cigarettes, with 27.5% of high schoolers and 10.5% of middle schoolers reporting current use. Among these current e-cigarette users, 34.2% of high schoolers and 18% of middle schoolers use e-cigarettes for 20 or more days each month.


Related Reading:


2FIRSTS special: Juul settlement summary


JUUL has spent $18.2 billion in hopes of reaching a settlement. Here is a breakdown of the settlement amounts and conditions in each state.


Juul has reached a $24 million settlement agreement with Chicago.


A US district court has approved a $255m class-action settlement with Juul prior to trial.


E-cigarette company JUUL has paid a total of $1.7 billion in settlements after 34 states filed lawsuits against the company.


References:


The state of West Virginia has come to an agreement with e-cigarette company Juul.



Disclaimer

This article is provided solely for professional research, industry discussion, and informational purposes. Any references to brands, companies, products, technologies, or policies are made for factual reporting and analytical purposes only, and do not constitute endorsement, recommendation, promotion, or advertising by 2Firsts.

Nicotine-containing products, including but not limited to cigarettes, e-cigarettes, heated tobacco products, and nicotine pouches, carry significant health risks. Readers are responsible for complying with all applicable laws and regulations in their respective jurisdictions, including age restrictions and access limitations.

The information contained in this article should not be regarded as investment, legal, medical, regulatory, or commercial advice. While 2Firsts strives to ensure the accuracy and reliability of its content, it does not assume liability for any direct or indirect loss arising from errors, omissions, inaccuracies, or reliance on the information contained herein.

This article is not intended for individuals below the legal age for accessing tobacco or nicotine-related information in their jurisdiction.

 

Copyright Notice

This article is either original content produced by 2Firsts or content reproduced, translated, summarized, or adapted from third-party sources with attribution where applicable. The intellectual property rights of the original content remain with 2Firsts or the respective original rights holders.

No individual or organization may copy, reproduce, distribute, republish, modify, translate, or otherwise use this content without prior authorization. Any unauthorized use may result in legal action.

For copyright-related inquiries, corrections, or removal requests, please contact: info@2firsts.com.

 

AI-Assisted Translation and Editing Notice

Portions of this article may have been translated, edited, or reviewed with the assistance of artificial intelligence tools to improve efficiency and readability. Due to the limitations of AI-assisted translation and editing, discrepancies, omissions, or inaccuracies may exist when compared with the original source.

Where applicable, readers are advised to refer to the original source for the most complete and accurate information. If you identify any errors or believe that any content infringes upon your rights, please contact us at info@2firsts.com, and we will review and address the matter promptly.

NAS 2026 | FDA CTP Director Says PMTA Pathway Is “Predicated on Tobacco Harm Reduction”
NAS 2026 | FDA CTP Director Says PMTA Pathway Is “Predicated on Tobacco Harm Reduction”
At the 2026 New Approaches Summit in New York, FDA Center for Tobacco Products Director Bret Koplow said the PMTA pathway is “predicated on tobacco harm reduction.” He outlined four CTP priorities: youth prevention, helping adults quit or switch to lower-risk products, improving relative-risk communication, and reducing unauthorized products. Koplow also addressed flavored e-cigarettes, public risk perceptions, industry credibility and efforts to make PMTA reviews more efficient and predictable.
Sep.26
From Product Innovation to Integrated Solutions: NEXTECH Expands Its Global Heated Tobacco Solutions
From Product Innovation to Integrated Solutions: NEXTECH Expands Its Global Heated Tobacco Solutions
NEXTECH launched its NEXE Pro circumferential-heating tobacco stick globally at InterTabac 2026, as the company expands from product innovation into broader heated tobacco solutions. Amid intensifying competition across global HTP markets, NEXTECH is strengthening its R&D, manufacturing and pre-launch support capabilities to serve different types of business customers.
Industry Insight
Sep.15
PMI Expands U.S. ZYN Portfolio With New 1.5 mg and 8 mg Strengths, Moves Toward a Unified 20-Pouch-Per-Can Format
PMI Expands U.S. ZYN Portfolio With New 1.5 mg and 8 mg Strengths, Moves Toward a Unified 20-Pouch-Per-Can Format
Philip Morris International is expanding its U.S. ZYN nicotine pouch portfolio with new 1.5 mg and 8 mg strengths and plans to move its core 3 mg and 6 mg dry-pouch products from 15 to 20 pouches per can in the fourth quarter of 2026. ZYN ULTRA is also commercially available, with FDA authorization covering 10 products at 9 mg and one 11 mg Smooth product. PMI U.S. lists the new 1.5 mg and 8 mg strengths as commercially available, but as of September 10 they do not appear on the FDA’s public authorization list. Public materials do not identify which PMTA submissions cover the two new strengths or their current review status.
Sep.11
FDA Authorizes JUUL2, Cites Adult Switching Amid Efforts to Speed PMTA Reviews
FDA Authorizes JUUL2, Cites Adult Switching Amid Efforts to Speed PMTA Reviews
The FDA authorized the JUUL2 device and tobacco- and menthol-flavored pods on Aug. 28, bringing the number of authorized e-cigarette products to 48. The agency highlighted complete switching among adult smokers, with six-week switching rates reaching 28.4%–49.3% for the menthol pod. The decision comes as FDA works to speed PMTA reviews, reduce application backlogs and expand authorized e-cigarette and nicotine-pouch products while maintaining enforcement priorities for unauthorized products.
Regulations
Aug.29
FDA Revises Import Alert 98-07 Rules, Bringing May Enforcement Priorities Into Unauthorized ENDS Detentions
FDA Revises Import Alert 98-07 Rules, Bringing May Enforcement Priorities Into Unauthorized ENDS Detentions
The U.S. Food and Drug Administration has revised the rules under Import Alert 98-07 to incorporate its May 2026 enforcement-priority policy for certain electronic nicotine delivery systems marketed without premarket authorization. The alert continues to allow detention without physical examination, or DWPE, for ENDS lacking required marketing authorization, while directing field divisions to apply the May risk-based framework. When necessary, detention or refusal decisions must also undergo review by the FDA's Center for Tobacco Products. Products including PACHA and Vuse Pro have already emerged as industry examples of the May policy, although enforcement discretion does not constitute FDA marketing authorization.
News
Sep.28 by 2Firsts Perspectives
UK HMRC Unveils Red and Yellow Transitional Vape Duty Stamps Ahead of October Tax Launch
UK HMRC Unveils Red and Yellow Transitional Vape Duty Stamps Ahead of October Tax Launch
HM Revenue & Customs (HMRC) has released sample images of the UK’s transitional vaping duty stamps, showing red and yellow versions ahead of the new Vaping Products Duty and Vaping Duty Stamps Scheme starting on October 1, 2026. Transitional stamps contain physical security features but no digital scanning function. Approved businesses may purchase them through November 30 and affix them through December 31. HMRC has not stated that the red and yellow samples represent different product categories or tax statuses.
Regulations
Sep.02